United States President Donald Trump, Eli Lilly and Novo Nordisk have unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for the government’s Medicare and Medicaid programme, as well as for cash payers.

The deal, announced on Thursday, is aimed at increasing access to treatments through US Medicare for people aged 65 and above and the Medicaid programme for low-income people, which together provide healthcare coverage for nearly half of all Americans.

US patients currently pay by far the most for prescription medicines, often nearly three times more than in other developed nations, and Trump has been pressuring drugmakers to lower their prices to what patients pay elsewhere.

“It’s going to equalise the world,” Trump told reporters from the Oval Office, noting that Li

See Full Page